La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Phathom Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Phathom Pharmaceuticals..

Phathom Pharmaceuticals (NASDAQ:PHAT) Azioni, Catena delle Opzioni

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

News

ADEA

Adeia Files Multiple Patent Infringement Lawsuits Against Disney, Hulu, And ESPN In U.S. And Europe; Legal Actions Initiated In Delaware And Across European Courts

NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.30) by 100 percent. This is a 95.42 percent increase over losses of $(13.11) per share from the same period last year. The company reported quarterly sales of $2.44 million which missed the analyst consensus estimate of $2.62 million by 6.94 percent. This is a 1.61 percent decrease over sales of $2.48 million the same period last year.

Earnings

Earnings Misses

NovaBay Pharmaceuticals Q3 EPS $(0.60) Misses $(0.30) Estimate, Sales $2.44M Miss $2.62M Estimate

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16.67 percent. The company reported quarterly sales of $102.073 million which missed the analyst consensus estimate of $102.718 million by 0.63 percent. This is a 4.69 percent decrease over sales of $107.095 million the same period last year.

UEIC

Universal Electronics Q3 2024 Adj. EPS $0.10 Misses $0.12 Estimate, Sales $102.073M Miss $102.718M Estimate

Guidance

BNED

Barnes & Noble Education Sees Prelim Q2 First Day Program Revenue $235M

Metallus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.02) by 350 percent. The company reported quarterly sales of $227.200 million which missed the analyst consensus estimate of $274.367 million by 17.19 percent. This is a 35.86 percent decrease over sales of $354.200 million the same period last year.

MTUS

Metallus Q3 2024 Adj. EPS $(0.09) Misses $(0.02) Estimate, Sales $227.200M Miss $274.367M Estimate

ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent.

LOGC

ContextLogic Q3 2024 GAAP EPS $(0.04) Misses $(0.01) Estimate

Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(0.98) by 3.06 percent. This is a 35.71 percent decrease over losses of $(0.70) per share from the same period last year.

Earnings Beats

PLRX

Pliant Therapeutics Q3 EPS $(0.95) Beats $(0.98) Estimate

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $36.325 million which beat the analyst consensus estimate of $35.609 million by 2.01 percent. This is a 7.39 percent decrease over sales of $39.222 million the same period last year.

ONTF

ON24 Q3 2024 Adj. EPS $0.02 Beats $0.00 Estimate, Sales $36.325M Beat $35.609M Estimate

Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(1.11) by 8.11 percent. The company reported quarterly sales of $24.564 million which missed the analyst consensus estimate of $26.657 million by 7.85 percent. This is a 32.57 percent decrease over sales of $36.427 million the same period last year.

SKLZ

Skillz Q3 2024 GAAP EPS $(1.20) Misses $(1.11) Estimate, Sales $24.564M Miss $26.657M Estimate

Management

Eventbrite Appoints Anand Gandhi As CFO, Effective Nov. 19; Lanny Baker Shifts Focus To COO Role To Drive Operational Excellence And Growth

Transcontinental Realty Q3 EPS $0.20 Down From $0.52 YoY, Sales $11.607M Down From $12.525M YoY

Olo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 50 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $71.853 million which beat the analyst consensus estimate of $70.940 million by 1.29 percent. This is a 24.33 percent increase over sales of $57.794 million the same period last year.

Olo Q3 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $71.853M Beat $70.940M Estimate

Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. The company reported quarterly sales of $10.867 million which missed the analyst consensus estimate of $12.091 million by 10.12 percent. This is a 36.78 percent decrease over sales of $17.190 million the same period last year.

TACT

Transact Technologies Q3 2024 GAAP EPS $(0.06) Beats $(0.08) Estimate, Sales $10.867M Miss $12.091M Estimate

WIIM

UPST

Upstart Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.41) by 151.22 percent. This is a 160 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $71.75 million which beat the analyst consensus estimate of $16.27 million by 340.98 percent. This is a 667.19 percent increase over sales of $9.35 million the same period last year.

PSTX

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

Offerings

GEHC

GE HealthCare Technologies Inc. Announces Launch Of Secondary Offering Of 13,281,302 Shares

This agreement is part of an initial deal with FPM as they continue to drive the energy transition with utilities in California. FPM selected Bloom Energy's solution due to the following benefits:

Contracts

Bloom Energy Secures 20 MW Utility Deal With FPM Development; Terms Not Disclosed

President-elect Donald Trump campaigned on placing high tariffs on competing nations and cutting taxes, so what should investors expect after <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">Trump&#8217;s second inauguration</a>?
Trump&#8217;s Policy: Trump&#8217;s specific plans concerning tariffs and taxes are unclear and have varied greatly. The 2024 Republican Party <a href="https://www.presidency.ucsb.edu/documents/2024-republican-party-platform">platform</a> calls for &#8220;baseline Tariffs on Foreign-made goods.&#8221; <a href="https://taxpolicycenter.org/taxvox/tpc-trump-tariffs-would-raise-household-taxes-and-slow-imports">According</a> to the Tax Policy Center, Trump most often promotes a 10% worldwide tariff and a 60% tax on imported Chinese goods.
Trump supports extending his 2017 Tax Cuts and Jobs Act and further reducing taxes. He has also <a href="https://www.benzinga.com/government/24/06/39319275/no-income-tax-yes-to-high-import-tariffs-trump-floats-idea-to-ceos-gop-lawmakers">floated the idea </a>of abolishing the federal income tax entirely.
What&#8217;s Next: Replacing federal income tax with tariffs would be an enormous policy shift that would likely require extensive legislative action and significant changes to the U.S. tax code. 
To replace federal income tax with tariffs, Congress would need to pass legislation that either drastically reduces income tax rates or repeals them altogether. This legislation would require significant support in both the House and Senate. To generate revenue, Congress would need to enact new laws imposing or increasing tariffs on a wide range of imported goods.
Given that taxes are among the most complex areas of the law, the final version of Trump&#8217;s policy would likely differ from his campaign promises.
Potential Impact: The Tax Foundation <a href="https://taxfoundation.org/blog/trump-tariffs-revenue-estimates/">estimated</a> the economic impact following Trump&#8217;s victory.
The think tank forecast that, from 2025 through 2034, a 10% universal tariff would raise $2 trillion, while a 20% universal tariff would raise $3.3 trillion. A 10% tariff would increase average taxes on U.S. households by $1,253, while a 20% tariff would increase taxes on U.S. households by $2,045.
These potential tariff revenues would make up only a small fraction of total U.S. individual income tax collections. Thus, a sharp reduction in federal taxes would need to be supplanted by cuts to health care, Social Security, military spending or veterans benefits to limit the federal government deficit.
Is This Even Possible? Trump&#8217;s stated positions are more popular among the public than they are among economists.
The Peterson Institute for International Economics&#8217;s Kimberly Clausing and Maurice Obstfeld <a href="https://www.piie.com/blogs/realtime-economics/2024/can-trump-replace-income-taxes-tariffs">wrote</a> in June that replacing income taxes with tariffs would harm economic growth.
&#8220;For starters, it would cost jobs, ignite inflation, increase federal deficits, and cause a recession. It would also shift the tax burden away from the well-off, substantially increasing the tax burden on the poor and middle class,&#8221; the economists wrote. 
&#8220;If pursued, this policy would antagonize U.S. allies and partners, provoking worldwide trade wars, damaging global economic welfare, and undermining national security. It would also likely destabilize the global financial system,&#8221; they added.
Political opponent Bernie Sanders (I-VT) has <a href="https://www.benzinga.com/news/24/10/41642184/bernie-sanders-says-trumps-plan-to-eliminate-all-income-taxes-is-insane-economics-will-trigger-the-b">voiced disapproval</a> of Trump&#8217;s proposals, calling them &#8220;insane economics.&#8221;
"This would be the biggest transfer of wealth in the history of this country. It would mean the billionaire class, the millionaires, no longer pay a nickel in taxes,&#8221; Sanders wrote on X.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
Photo: Shutterstock.

Government

Politics

Economics

Trump Says He'd Replace Income Taxes With Tariffs: The Potential Economic Fallout

Amplitude (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPL#NASDAQ">AMPL</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. This is a 40 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $75.217 million which beat the analyst consensus estimate of $74.118 million by 1.48 percent. This is a 6.48 percent increase over sales of $70.637 million the same period last year.

AMPL

Amplitude Q3 2024 Adj. EPS $0.03 Beats $0.01 Estimate, Sales $75.217M Beat $74.118M Estimate

LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $53.393 million which missed the analyst consensus estimate of $53.802 million by 0.76 percent. This is a 38.27 percent increase over sales of $38.614 million the same period last year.

LFMD

LifeMD Q3 2024 Adj. EPS $0.09 Beats $(0.12) Estimate, Sales $53.393M Miss $53.802M Estimate

Short-squeeze opportunities are tough to find. Combine market timing with fundamentals for these stocks.

These Are The Top 3 Most-Shorted Stocks In August 2024; Here's Why

Analyst Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) and keeping the price target at $2...

Phathom Pharmaceuticals' V oquezna: A Rising Star in GERD Treatment Market

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The associated price targe...

Phathom Pharmaceuticals' V oquezna Shows Promising Market Penetration and Drives Buy Rating

Following Up On Phathom Pharmaceuticals

Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $26.00....

Buy Rating Affirmed: Phathom Pharmaceuticals' V oquezna Shows Promising Market Penetration and Growth Potential

Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today. The company's shares cl...

Phathom Pharmaceuticals (PHAT) Gets a Buy from Craig-Hallum

Phathom Pharmaceuticals GAAP EPS of -$1.32 beats by $0.21, revenue of $16.4M beats by $3.99M

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with a price ...

Phathom Pharmaceuticals Surpasses Expectations: Strong Q3 Performance and Bullish Outlook Drive Increased Revenue Estimates and Price Target

BYND

GRPN

PHAT

Press Releases

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

Health Care

General

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

Comments

Phathom Pharmaceuticals

Phathom Pharmaceuticals (PHAT) Opzioni

Phathom Pharmaceuticals (NASDAQ:PHAT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO